Vaxon Biotech, Inc. (Vaxon)

Oncology Corporate Profile

HQ Location

3 rue de l'Arriv?©e
BP 191
Tout CIT, Paris 75749

Company Description

Vaxon Biotech specializes in anti-tumor immunotherapy through an innovative therapeutic approach which aims to stimulate the immune system to target and destroy tumor cells and halt tumor development. The company is currently developing four products, two in clinical development and two at the preclinical stage. The most advanced product in its portfolio, Vx-001, is a peptide based vaccine for HLA-A2-positive patients with TERT-expressing tumors. It has been in phase IIB trials for non-small-cell lung cancer (NSCLC) since 2012 (underway in eight European countries).


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Vx-001monopeptide TERTNon Small Cell Lung Cancer (NSCLC)II
Vx-006polypeptide TERTVarious cancer typesI
Vbx-016polypeptide TERTVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display